We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+28.98%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$243M
AUM Growth
+$38.5M
Cap. Flow
+$8.54M
Cap. Flow %
3.52%
Top 10 Hldgs %
96.47%
Holding
17
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$8.54M

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$13

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$160M 65.94%
6,068,125
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$18.2M 7.49%
1,115,352
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$14.9M 6.13%
1,025,000
– –
BMEA icon
4
Biomea Fusion
BMEA
$84.6M
$11M 4.53%
798,757
– –
CMPS
5
Compass Pathways
CMPS
$1.53B
$7.14M 2.94%
+964,500
New +$8.54M
GLUE icon
6
Monte Rosa Therapeutics
GLUE
$1.4B
$7.05M 2.91%
1,472,331
– –
OKUR
7
OnKure Therapeutics
OKUR
$154M
$6.74M 2.78%
88,608
– –
NUVB icon
8
Nuvation Bio
NUVB
$2.2B
$3.4M 1.4%
2,541,009
– –
ACRS icon
9
Aclaris Therapeutics
ACRS
$726M
$2.98M 1.23%
434,455
– –
SPRB
10
Spruce Biosciences
SPRB
$118M
$2.72M 1.12%
16,073
– –
PSTX
11
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$2.48M 1.02%
1,043,267
– –
ELEV
12
DELISTED
Elevation Oncology
ELEV
$1.88M 0.77%
2,834,910
– –
TECX
13
Tectonic Therapeutic
TECX
$529M
$1.56M 0.64%
84,148
– –
MRKR icon
14
Marker Therapeutics
MRKR
$18.8M
$1.43M 0.59%
314,286
– –
SYRE icon
15
Spyre Therapeutics
SYRE
$8.54B
$829K 0.34%
67,645
-1
-0% -$13
VIRX
16
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$300K 0.12%
288,571
– –
BCEL
17
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$101K 0.04%
387,653
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Aisling Capital Management held 17 positions worth $243M, up 19% from $204M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Aisling Capital Management deployed $8.54M of net new capital in Q3 2023, opening 1 new position. Its largest new stake was Compass Pathways: 964,500 shares worth $7.14M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Spyre Therapeutics, an estimated $13 trimmed.

  • Aisling Capital Management's largest Q3 2023 buy was Compass Pathways: 964,500 shares worth $7.14M.
  • Aisling Capital Management's biggest Q3 2023 reduction was Spyre Therapeutics, cutting an estimated $13.
  • Aisling Capital Management's ten largest holdings make up 96% of its $243M portfolio in Q3 2023.
  • Aisling Capital Management opened 1 new position and closed 0 in Q3 2023.
  • Aisling Capital Management's portfolio value rose 19% quarter-over-quarter to $243M.

Based on Aisling Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.